Drug Profile
Research programme: inflammation therapeutics - Almirall/Proteros
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Almirall S.A.; Proteros Biostructures
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Spain
- 26 Sep 2011 Early research in Inflammation in Spain (unspecified route)